/PRNewswire/ Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), today announced full results from the 16-HMedIdeS-12 phase 2 trial in patients with antibody.
Statistically significant reduction in donor-specific antibodies observed among imlifidase patients within five days of treatment as compared to standard of care
LUND, Sweden, Dec. 14, 2023.
Hansa Biopharma Nomination Committee formed streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Hansa Biopharma today announced positive high-level data from the 15-HMedIdeS-09 phase 2 trial that demonstrated imlifidase was safe and well tolerated when administered prior to standard of care, including rapid improvement in disease-related efficacy measures.
Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) and Hansa Biopharma AB (publ) (OTCMKTS:HNSBF – Get Free Report) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, risk, analyst recommendations, valuation, institutional ownership and profitability. Valuation and Earnings This table compares […]